GENPET: Targeted FCH-PET-CT imaging based on genetic profile
Research type
Research Study
Full title
An imaging study of PET-CT in men with prostate cancer and a DNA repair gene mutation
IRAS ID
138894
Contact name
Rosalind Eeles
Contact email
Sponsor organisation
The Institute of Cancer Research
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
GENPET aims to analyse the utility of a relatively new method of imaging called FCH-PET-CT scanning in men with a BRCA1/2 gene mutation. Men with these rare mutations in cancer predisposition genes who develop prostate cancer have been shown to have a higher incidence of metastatic disease and a worse prognosis.
This study will compare FCH-PET-CT to the standard staging investigations MRI and bone scan in this high risk group. All three of these scans are standard for this group of men at the Royal Marsden Hospital so no additional scans are being given as part of the study. The scans will be read twice, by specialists blinded to the other's interpretation and other scan results. The sensitivity of this scan will be compared to MRI and bone scan in this group.
REC name
London - Riverside Research Ethics Committee
REC reference
15/LO/0242
Date of REC Opinion
13 Mar 2015
REC opinion
Favourable Opinion